专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20090104209A1 METHODS OF REDUCING A VIRAL INFECTION AND KITS THEREFORE 失效
标题翻译：减少病毒感染的方法及其应用
公开(公告)号：US20090104209A1
公开(公告)日：2009-04-23
申请号：US12234027
申请日：2008-09-19
申请人： NABIL G. SEIDAH , PATRICK LABONTE
发明人： NABIL G. SEIDAH , PATRICK LABONTE
IPC分类号： A61K39/395 , C12N5/00 , A61K31/7052 , A61K38/16 , A61P31/12 , C12Q1/02 , A61K38/02 , C12Q1/70
CPC分类号： G01N33/569 , C07K14/70596 , C12N9/6408 , G01N2333/96411 , G01N2500/00 , G01N2800/50
摘要： A method for treating and/or preventing a proprotein convertase subtilisin/kexin type 9 preproprotein (PCSK9)-susceptible viral infection comprising increasing a PCSK9 activity and/or expression in a biological system infected by the virus, whereby the increased PCSK9 activity and/or expression treats and/or prevents the viral infection in the biological system. Methods of classifying subjects, methods of screening and kits therefore.
摘要翻译：用于治疗和/或预防前体蛋白转化酶枯草杆菌蛋白酶/ kexin 9型前蛋白（PCSK9） - 易感性病毒感染的方法，包括增加感染病毒的生物系统中的PCSK9活性和/或表达，由此增加的PCSK9活性和/或表达治疗和/或预防生物系统中的病毒感染。因此分类科目的方法，筛选方法和试剂盒。

2. 发明授权

US08088571B2 Methods of reducing a viral infection and kits therefore 失效
标题翻译：因此减少病毒感染的方法
公开(公告)号：US08088571B2
公开(公告)日：2012-01-03
申请号：US12234027
申请日：2008-09-19
申请人： Nabil G. Seidah , Patrick Labonté
发明人： Nabil G. Seidah , Patrick Labonté
IPC分类号： C12Q1/70 , A61K38/00 , A01N37/18 , A61P1/16
CPC分类号： G01N33/569 , C07K14/70596 , C12N9/6408 , G01N2333/96411 , G01N2500/00 , G01N2800/50
摘要： A method for treating and/or preventing a proprotein convertase subtilisin/kexin type 9 preproprotein (PCSK9)-susceptible viral infection comprising increasing a PCSK9 activity and/or expression in a biological system infected by the virus, whereby the increased PCSK9 activity and/or expression treats and/or prevents the viral infection in the biological system. Methods of classifying subjects, methods of screening and kits therefore.
摘要翻译：用于治疗和/或预防前体蛋白转化酶枯草杆菌蛋白酶/ kexin 9型前蛋白（PCSK9） - 易感性病毒感染的方法，包括增加感染病毒的生物系统中的PCSK9活性和/或表达，由此增加的PCSK9活性和/或表达治疗和/或预防生物系统中的病毒感染。因此分类科目的方法，筛选方法和试剂盒。

3. 发明授权

US08187833B2 Chimeric PCSK9 proteins, cells comprising same, and assays using same 有权
标题翻译：嵌合PCSK9蛋白，包含其的细胞和使用其的测定
公开(公告)号：US08187833B2
公开(公告)日：2012-05-29
申请号：US12300148
申请日：2007-05-08
申请人： Nabil G. Seidah , Jean Davignon , Geneviève Dubuc , Lise Bernier , Michel Tremblay
发明人： Nabil G. Seidah , Jean Davignon , Geneviève Dubuc , Lise Bernier , Michel Tremblay
IPC分类号： C12Q1/37 , G01N33/48
CPC分类号： G01N33/5008 , A61K38/00 , C07K16/40 , C07K2319/01 , C07K2319/03 , C12N9/6424
摘要： A chimera protein comprising in the following order: a signal peptide, a proprotein convertase subtilisin/kexin type 9 preproprotein (PCSK9) sequence consisting of amino acid residues at positions 35 to 696 of SEQ ID NO: 38, a transmembrane domain and a cytosolic domain, wherein said cytosolic (CT) domain comprises a sequence able to recycle the protein from the cellular membrane to endosomes.
摘要翻译：包含以下顺序的嵌合体蛋白质：信号肽，由SEQ ID NO：38的35至696位的氨基酸残基组成的前蛋白转化酶枯草杆菌蛋白酶/ kexin 9型前蛋白（PCSK9）序列，跨膜结构域和胞质结构域，其中所述细胞溶质（CT）结构域包含能够将蛋白从细胞膜再循环到内体的序列。

4. 发明授权

US5789564A Development of research diagnostic and production tools for pro-hormone convertases 失效
标题翻译：开发激素转化酶的研究诊断和生产工具
公开(公告)号：US5789564A
公开(公告)日：1998-08-04
申请号：US712241
申请日：1996-09-12
申请人： Nabil G. Seidah , Michel Chretien
发明人： Nabil G. Seidah , Michel Chretien
IPC分类号： A61K39/395 , B01D15/08 , C07H21/00 , C07K17/10 , C12N9/64 , C12N15/57 , C12N15/86 , C12Q1/68 , G01N33/573 , C07H21/04
CPC分类号： C12N9/6454 , C07K2319/00
摘要： The present invention relates to pro-hormone convertases and polypeptidic fragments thereof, nucleic acids encoding them, recombinant viruses expressing these convertases, polyclonal antibodies directed against the convertases, diagnostic kits for the detection and measurement of the convertase content in cell or tissue lysates, culture media or biological fluids by RIA. Diagnostic kits were also developped for detection or measurement of nucleic acids, preferably mRNAs, in cell or tissue lysates by hybridization. The invention also concerns oligonucleotides useful as probes or as primers for DNA synthesis. These oligonucleotides were included in the diagnostic kits as well as used for the obtention of specific fragments of the convertases which have served, together with native convertases, as antigens for the obtention of antibodies. The convertases were produced by mammalian cell lines transfected with the recombinant viruses and purified on affinity columns which are also an object of the invention. Processes for producing the native convertases, fragments thereof and antibodies are also described and claimed.
摘要翻译：本发明涉及前激素转化酶及其多肽片段，编码它们的核酸，表达这些转化酶的重组病毒，针对转化酶的多克隆抗体，用于检测和测量细胞或组织裂解物中转化酶含量的诊断试剂盒，培养物培养基或生物液体。还开发了诊断试剂盒，用于通过杂交检测或测量细胞或组织裂解物中的核酸，优选mRNA。本发明还涉及可用作探针或用作DNA合成的引物的寡核苷酸。这些寡核苷酸被包括在诊断试剂盒中，并且用于获得已经与天然转化酶一起服用作为获得抗体的抗原的转化酶的特异性片段。转化酶由用重组病毒转染的哺乳动物细胞系产生，并且在亲和柱上纯化也是本发明的目的。还描述和要求保护天然转化酶，其片段和抗体的方法。

5. 发明授权

US08673850B2 PCSK9 inhibitors and methods of use thereof 有权
标题翻译： PCSK9抑制剂及其使用方法
公开(公告)号：US08673850B2
公开(公告)日：2014-03-18
申请号：US12994835
申请日：2009-06-01
申请人： Nabil G. Seidah , Gaétan Mayer , Steve Poirier
发明人： Nabil G. Seidah , Gaétan Mayer , Steve Poirier
IPC分类号： A61K38/00 , A61P3/06 , C12N5/00 , C12N5/02 , C07K5/00 , C07K7/00 , C07K16/00 , C07K17/00 , C12P21/08 , C07H21/04
CPC分类号： C07K16/40 , A61K38/00 , A61K39/39533 , A61K45/06 , C07K14/4721 , C07K2317/77 , G01N33/5023 , G01N33/68 , G01N2333/4718 , G01N2500/00 , G01N2800/044 , A61K2300/00
摘要： A method for identifying a compound for preventing or treating a LDLR-associated disease, a VLDLR-associated disease or an ApoER2-associated disease, said method comprising determining whether: a) a level of expression of Annexin A2 nucleic acid or encoded polypeptide; b) a level of Annexin A2 activity; or c) a combination of a) and b), is increased in the presence of a test compound relative to in the absence of said test compound, wherein said increase is indicative that said test compound can be used for preventing or treating a LDLR-associated disease, a VLDLR-associated disease, an ApoER2-associated disease.
摘要翻译：鉴定用于预防或治疗LDLR相关疾病，VLDLR相关疾病或ApoER2相关疾病的化合物的方法，所述方法包括确定：a）膜联蛋白A2核酸或编码多肽的表达水平; b）膜联蛋白A2活性水平; 或c）a）和b）的组合在测试化合物存在下相对于不存在所述测试化合物而增加，其中所述增加表明所述测试化合物可用于预防或治疗LDLR- 相关疾病，VLDLR相关疾病，ApoER2相关疾病。

6. 发明申请

US20120237945A1 CHIMERIC PCSK9 PROTEINS, CELLS COMPRISING SAME, AND ASSAYS USING SAME 有权
标题翻译： CHIMERIC PCSK9蛋白，包含其的细胞和使用相同的测定法
公开(公告)号：US20120237945A1
公开(公告)日：2012-09-20
申请号：US13460029
申请日：2012-04-30
申请人： NABIL G. SEIDAH , JEAN DAVIGNON , GENEVIÉVE DUBUC , LISE BERNIER , MICHEL TREMBLAY
发明人： NABIL G. SEIDAH , JEAN DAVIGNON , GENEVIÉVE DUBUC , LISE BERNIER , MICHEL TREMBLAY
IPC分类号： G01N33/573 , C12N9/50 , C07K16/40
CPC分类号： G01N33/5008 , A61K38/00 , C07K16/40 , C07K2319/01 , C07K2319/03 , C12N9/6424
摘要： A chimera protein comprising in the following order: a signal peptide, a proprotein convertase subtilisin/kexin type 9 preproprotein (PCSK9) sequence consisting of amino acid residues at positions 35 to 696 of SEQ ID NO: 38, a transmembrane domain and a cytosolic domain, wherein said cytosolic (CT) domain comprises a sequence able to recycle the protein from the cellular membrane to endosomes.
摘要翻译：包含以下顺序的嵌合体蛋白质：信号肽，由SEQ ID NO：38的35至696位的氨基酸残基组成的前蛋白转化酶枯草杆菌蛋白酶/ kexin 9型前蛋白（PCSK9）序列，跨膜结构域和胞质结构域，其中所述细胞溶质（CT）结构域包含能够将蛋白从细胞膜再循环到内体的序列。

7. 发明授权

US06380171B1 Pro-protein converting enzyme 失效
标题翻译：前蛋白转化酶
公开(公告)号：US06380171B1
公开(公告)日：2002-04-30
申请号：US09214555
申请日：1999-09-13
申请人： Robert Day , Nabil G. Seidah , Rémi Martel , Michel Chrétien , Tim Reudelhuber , Guy LeClerc
发明人： Robert Day , Nabil G. Seidah , Rémi Martel , Michel Chrétien , Tim Reudelhuber , Guy LeClerc
IPC分类号： A61K3170
CPC分类号： C12N9/6454 , A61K38/00
摘要： The present invention relates to the cloning of human pro-protein converting enzyme 5 (PC5) CDNA isolated from human adrenal gland messenger RNA. Additionally, this invention relates to a method for reducing restenosis occurring at an injured vascular site comprising delivering to the injured site an antisense nucleic acid to suppress the expression of human PC5.
摘要翻译：本发明涉及从人肾上腺信使RNA分离的人前蛋白转化酶5（PC5）CDNA的克隆。此外，本发明涉及一种减少在受伤的血管部位发生的再狭窄的方法，包括将受损部位输送到反义核酸以抑制人PC5的表达。

8. 发明授权

US5840529A Mammalian pro-hormone convertase 失效
标题翻译：哺乳动物前体激素转化酶
公开(公告)号：US5840529A
公开(公告)日：1998-11-24
申请号：US545562
申请日：1995-10-19
申请人： Nabil G. Seidah , Robert Day , Michel Chretien
发明人： Nabil G. Seidah , Robert Day , Michel Chretien
IPC分类号： G01N33/50 , A61K48/00 , C07K14/16 , C07K16/40 , C12N5/00 , C12N5/10 , C12N9/64 , C12N15/09 , C12N15/57 , C12P21/00 , C12Q1/68 , C12R1/91 , G01N33/53 , C07H21/04 , C07K14/00 , C12N15/63
CPC分类号： C07K14/005 , C12N9/6454 , A61K48/00 , C12N2740/16122
摘要： This invention relates to a novel and seventh member of the subtilisin-kexin family isolated from rat, which has been named rPC7. The rat spleen cDNA has been totally sequenced. A shorter DNA sequence has been obtained for human, which corresponds to a portion of the catalytic region of a human pro-hormone convertase corresponding to the rat pro-hormone convertase. PC7 clearly distinguishes from the other mammalian members of the subtilisin-kexin family. Its tissue distribution is ubiquitous, but its presence is particularly remarkable in lymphoid tissues. It is present in LoVo cells that are able to cleave the HIV gp160 protein into active gp120/gp41 proteins and that are deficient in other effective pro-hormone convertases known up to date. Therefore, it is proposed that PC7 is a good candidate as a maturation enzyme responsible for the conversion of HIV gp160 protein in target CD.sup.+4 cells.
摘要翻译：本发明涉及从大鼠中分离的枯草杆菌蛋白酶-Kexin家族的新颖和第七个成员，其被命名为rPC7。大鼠脾脏cDNA已经完全测序。人类已经获得了较短的DNA序列，其对应于对应于大鼠前体激素转化酶的人类前体激素转化酶的一部分催化区域。 PC7明显区别于枯草杆菌蛋白酶-Kexin家族的其他哺乳动物成员。其组织分布普遍存在，但其淋巴组织中的存在特别显着。它存在于能够将HIV gp160蛋白切割成活性gp120 / gp41蛋白质的LoVo细胞中，并且缺乏其他已知的有效的促激素转化酶。因此，建议PC7作为负责在目标CD + 4细胞中转染HIV gp160蛋白质的成熟酶的良好候选物。

9. 发明授权

US08338568B2 Chimeric PCSK9 proteins, cells comprising same, and assays using same 有权
公开(公告)号：US08338568B2
公开(公告)日：2012-12-25
申请号：US13460029
申请日：2012-04-30
申请人： Nabil G. Seidah , Jean Davignon , Genevieve Dubuc , Lise Bernier , Michel Tremblay
发明人： Nabil G. Seidah , Jean Davignon , Genevieve Dubuc , Lise Bernier , Michel Tremblay
IPC分类号： C07K14/435
CPC分类号： G01N33/5008 , A61K38/00 , C07K16/40 , C07K2319/01 , C07K2319/03 , C12N9/6424
摘要： A chimera protein comprising in the following order: a signal peptide, a proprotein convertase subtilisin/kexin type 9 preproprotein (PCSK9) sequence consisting of amino acid residues at positions 35 to 696 of SEQ ID NO: 38, a transmembrane domain and a cytosolic domain, wherein said cytosolic (CT) domain comprises a sequence able to recycle the protein from the cellular membrane to endosomes.

10. 发明申请

US20110118181A1 PCSK9 INHIBITORS AND METHODS OF USE THEREOF 有权
标题翻译： PCSK9抑制剂及其使用方法
公开(公告)号：US20110118181A1
公开(公告)日：2011-05-19
申请号：US12994835
申请日：2009-06-01
申请人： Nabil G. Seidah , Gaétan Mayer , Steve Poirier
发明人： Nabil G. Seidah , Gaétan Mayer , Steve Poirier
IPC分类号： A61K38/17 , C12Q1/68 , G01N33/68 , C12N5/071 , C07K14/47 , C07K16/18 , C07H21/00 , C12N15/63 , C12N5/10 , A61P3/00
CPC分类号： C07K16/40 , A61K38/00 , A61K39/39533 , A61K45/06 , C07K14/4721 , C07K2317/77 , G01N33/5023 , G01N33/68 , G01N2333/4718 , G01N2500/00 , G01N2800/044 , A61K2300/00
摘要： A method for identifying a compound for preventing or treating a LDLR-associated disease, a VLDLR-associated disease or an ApoER2-associated disease, said method comprising determining whether: a) a level of expression of Annexin A2 nucleic acid or encoded polypeptide; b) a level of Annexin A2 activity; or c) a combination of a) and b), is increased in the presence of a test compound relative to in the absence of said test compound, wherein said increase is indicative that said test compound can be used for preventing or treating a LDLR-associated disease, a VLDLR-associated disease, an ApoER2-associated disease.
摘要翻译：鉴定用于预防或治疗LDLR相关疾病，VLDLR相关疾病或ApoER2相关疾病的化合物的方法，所述方法包括确定：a）膜联蛋白A2核酸或编码多肽的表达水平; b）膜联蛋白A2活性水平; 或c）a）和b）的组合在测试化合物存在下相对于不存在所述测试化合物而增加，其中所述增加表明所述测试化合物可用于预防或治疗LDLR- 相关疾病，VLDLR相关疾病，ApoER2相关疾病。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式